Niddazol (Itraconazole)

Itraconazole blocks the fungal enzyme lanosterol 14α‑demethylase, a cytochrome P450 isoform essential for converting lanosterol to ergosterol. By preventing ergosterol synthesis, the drug disrupts fungal cell‑membrane integrity, inhibiting growth and leading to cell death.

The appropriate dose of Niddazol is determined by the prescribing clinician based on the specific infection, patient weight, renal and hepatic function, and other individual factors. No fixed regimen is provided here.

Safety data for itraconazole in pregnancy and lactation are limited. The product should be avoided unless the potential therapeutic benefit justifies the possible risk to the fetus or infant, and the decision must be made by a qualified health professional.

To request Niddazol, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with fluconazole, another azole antifungal, itraconazole (Niddazol) has a broader spectrum against molds such as Aspergillus and offers better activity for certain dimorphic fungi. However, itraconazole has more potential for drug‑drug interactions and requires monitoring of liver function.

Niddazol should be stored at ambient temperature, preferably below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid storing in humid or excessively hot environments.

Niddazol is administered orally, usually with food or a full glass of water to enhance absorption. The tablet or capsule should be swallowed whole and not crushed or chewed unless specifically instructed by a healthcare professional.

Serious adverse events include hepatotoxicity (elevated liver enzymes or liver injury), severe skin reactions such as Stevens‑Johnson syndrome, cardiac failure in patients with pre‑existing heart disease, and visual disturbances. Prompt medical attention is required if any of these occur.

Niddazol is contraindicated in individuals with known hypersensitivity to itraconazole or any azole antifungal. It should also be avoided in patients with severe hepatic impairment and in those taking contraindicated medications that strongly induce CYP3A4, such as rifampin.